WuXi Biologics (OTCPK:WXXWY) will take over the operations of one of Bayer’s (OTCPK:BAYRY) final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.
The plant includes a state-of-the-art vial filling line with isolators and two lyophilizers of 20 square meters each. Based on a manufacturing agreement to be negotiated, the plant would be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry, an antihemophilic factor (recombinant).
The transaction should close in the coming months.
Charles River Labs teams up with Fios Genomics in bioinformatics
Charles River Laboratories (NYSE:CRL) enters into an exclusive partnership with Fios Genomics under which CRL’s customers will have access to Fios’ know-how in bioinformatics, statistics and biology to enhance their drug development efforts, including microarrays, next-generation sequencing, proteomics, metabolomics, epigenetics and relevant metadata.
MorphoSys and Incyte team up to advance tafasitamab in $2B deal
MorphoSys AG (NASDAQ:MOR) inks a global collaboration and licensing agreement with Incyte (NASDAQ:INCY) to further develop and commercialize anti-CD19 monoclonal antibody tafasitamab.
The companies will co-commercialize tafasitamab in the U.S. with MOR leading strategy and booking all sales but equally sharing profits and losses. Ex-U.S., INCY will have exclusive commercialization rights, lead strategy and book all sales (paying royalties to MOR). INCY and MOR will share development costs associated with global and U.S.-specific studies on a 55/45 basis with INCY covering 100% of development costs for studies specific to ex-U.S. countries.
Under the terms of the deal, MOR will receive $750M upfront, up to $1.1B in milestones and tiered mid-teen-to-mid-twenties royalties on net sales. INCY will also make a $150M investment in MOR via the purchase of American Depositary Shares.
Owens & Minor to sell Movianto business
Owens & Minor (NYSE:OMI) intends to sell its European logistics business, Movianto, to EHDH Holding Group, a privately held French company.
The transaction is expected to close in H1 2020. Sale proceeds will be used for debt reduction.
Update: The sale price is ~$133M per a regulatory filing.
BioNTech to acquire Neon Therapeutics in all-stock deal
BioNTech SE (NASDAQ:BNTX) has agreed to acquire Neon Therapeutics (NASDAQ:NTGN) in an all-stock transaction valued at ~$67M ($2.18/share). Under the terms of the deal, Neon shareholders will receive 0.063 of a BNTX ADS for each NEON common share held.
Neon’s lead candidate is NEO-PTC-01, a personalized neoantigen-targeted T cell therapy.